


|


Financial Highlights:
(All figures are expressed in millions of Mexican pesos of purchasing
power as of
- Sales for the quarter grew 4.90% to reach $7,009.53 million
- Gross income increased 2.43%
- The gross margin for the quarter was 10.87%
- Quarterly operating expenses as a percentage of sales were 7.87%,
slightly higher than
the margin of 7.75% registered during the third quarter of 2008
- Operating income decreased 6.93% versus 3Q08
- The operating margin for the quarter was 3.00%
- The CCF for the quarter declined 22.15%
- Tax provisions were 61.14% lower than in 3Q08
- Net profit for the quarter was $155.38 million, an increase of 39.03%
- Cash and cash equivalents at the end of the quarter was $161.17 million
QUARTERLY EARNINGS
NET SALES
During the third quarter of 2009, GCS's sales were
SALES BY DIVISION
Private Pharma
Sales in our Private Pharma division rose 6.19% during the third quarter of 2009. This growth was primarily driven by our Mexican pharmaceutical distribution business.
Sales for this division reached
GOVERNMENT PHARMA
Sales in our Government Pharma division this quarter grew 5.19% to
As a percentage of total sales, this division went from representing 3.83% in 3Q08 to 3.84% during the third quarter of 2009.
HEALTH, BEAUTY, CONSUMER GOODS, GENERAL MERCHANDISE AND OTHER
Sales in our Health, Beauty, Consumer Goods, General Merchandise and Other
division reached
This division represented 8.49% of GCS's total sales in 3Q09, slightly lower than the same period of the previous year when it accounted for 9.19% of the Group's total sales.
PUBLICATIONS
Publication sales decreased 6.39% during the quarter, primarily as a result of lower unit sales. This decrease in units was due to the fact that Citem stopped distributing publications to international clients as well as some publications that no longer met our minimal profitability requirements.
Consequently, this division's participation as a percentage of total sales went from 3.09% in 3Q08 to 2.76% in the third quarter of 2009.
There were marginal changes in the sales mix during the quarter. Private Pharma sales represented 84.91% of total sales (compared to 83.88% during the third quarter of 2008), while Government Pharma accounted for 3.84% (versus 3.83% during the third quarter of 2008). Health, Beauty, Consumer Goods, General Merchandise and Other represented 8.49% (compared to 9.19% in the third quarter of 2008) and Publications made up the remaining 2.76% (versus 3.09% during the third quarter of 2008).
GROSS INCOME
During the third quarter of the year,
The company's gross margin was 10.87%, 26 basis points lower than the 11.13% margin posted during 3Q08. The margin was affected by an increase in the cost of sales resulting from less favorable commercial conditions with the main Brazilian wholesalers.
OPERATING EXPENSES
GCS's operating expenses reached
Operating expenses represented 7.87% of our total sales in 3Q09 compared to 7.75% during the same period of the previous year.
OPERATING INCOME
Quarterly operating income was
The operating margin was 3.00%, 38 basis points lower than the 3.38% margin registered in the third quarter of 2008.
OPERATING INCOME PLUS DEPRECIATION AND AMORTIZATION
Operating income plus depreciation and amortization for 3Q09 was
CASH AND CASH EQUIVALENTS
Cash and cash equivalents at the end of the third quarter of 2009 was
COMPREHENSIVE COST OF FINANCING
During the period, GCS's comprehensive cost of financing (CCF) reached
These interest payments are related to the long-term credit that was
obtained as a result of the acquisition in
OTHER EXPENSES (INCOME)
During the third quarter of 2009, the Company registered an income of
TAX PROVISIONS
During the third quarter, tax provisions were
The effective tax rate for the quarter was 13.74%.
NET INCOME
As a result, GCS's net income for the third quarter was
WORKING CAPITAL
During the third quarter of 2009, our accounts receivable days increased by 7.3 days from 3Q08 to reach 69.3 days. In addition, our accounts payable days rose by 6.1 days versus 3Q08, to reach 56.3 days. Finally, our inventory days were 60.4 days, 0.7 fewer days compared to the same period of the previous year.
Contacts:
Grupo Casa Saba
Patrik Zielinski
+52 (55) 5284-6623
pzielinski@casasaba.com
Sandra Yatsko
+52 (55) 5284-6698
syatsko@casasaba.com
IR Communications
Jesus Martinez Rojas
+52 (55) 5644-1247
jesus@irandpr.com
SOURCE



| ||||||
